Nav: Home

Community pharmacies make a lifestyle impact for patients with prostate cancer

June 12, 2019

Cardiovascular health and physical activity levels of prostate cancer patients improve following successful interventions by community pharmacies, new research in the British Medical Journal reports.

In the first study of its kind, researchers from the University of Surrey, funded by the Movember Foundation in partnership with Prostate Cancer UK, developed and tested the feasibility of community pharmacies delivering programmes to improve levels of physical activity and diet of men with prostate cancer and those who have successfully completed treatment for the disease. NICE recommends that men with prostate cancer follow a 12-week exercise programme to reduce symptoms after treatment and improve overall wellbeing, but this is hard to support in a hospital setting.

Nine community pharmacy teams in the south of England were trained to deliver health assessments and lifestyle prescriptions to men with prostate cancer or those who had undergone treatment. Pharmacy teams checked the weight, BMI, blood cholesterol and blood pressure of 116 men and assessed their upper-limb strength (grip strength), lower-limb strength (chair sit to stand) and overall fitness. To help improve strength and fitness levels, a computer algorithm developed by the research team used this assessment data to generate a personalised lifestyle prescription, including exercise and dietary advice, for the participants. In support of the lifestyle changes, pharmacy teams made regular phone calls to assist participants and offer guidance.

After a three-month period, participants were invited back to the pharmacy to assess progress. Moderate and vigorous physical activity levels amongst the group were found to have increased significantly by 34 minutes over three months. A reduction in weight by 1kg on average was observed amongst participants, with BMI down by 0.3kg/m2 and cholesterol decreasing by 0.4mmol/l. Grip strength increased on average by 0.2kg (meaning that men were stronger in their arms) and more chair sit to stands reflected better leg strength. These results indicate that support offered by community pharmacies can make a real difference in improving the physical fitness and wellbeing of men.

Sara Faithfull, Professor of Cancer Nursing Practice at the University of Surrey, said: "Exercise and diet have been shown to reduce symptoms of prostate cancer treatment and lessen chances of cardiovascular disease. It is understandable that men who have successfully beaten cancer are reluctant to embark on an exercise regime by themselves, so they need help to know what to do and how much is required to make a difference."

"Community pharmacies can make a really positive impact to this issue by providing valuable guidance and support for increasing activity levels and ensuring more informed dietary decisions are made. It is encouraging to see a measurable improvement over only three months, but we need to examine further how this could be effective in the longer term."

Heather Blake, Director of Support and Influencing from Prostate Cancer UK said: "We know that regular exercise and a healthy diet can help some men manage many of the side effects of prostate cancer treatments, as well as improving their mental health and wellbeing.

"We are therefore pleased that this study shows that community pharmacies can support men with prostate cancer to improve their physical activity and cardiovascular health. We now need to determine how this improvement can be sustained over longer periods of time."
-end-


University of Surrey

Related Prostate Cancer Articles:

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
New findings concerning hereditary prostate cancer
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
New test for prostate cancer significantly improves prostate cancer screening
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
The dilemma of screening for prostate cancer
Primary care providers are put in a difficult position when screening their male patients for prostate cancer -- some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients.
Risk factors for prostate cancer
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk.
Prostate cancer is 5 different diseases
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
UH Seidman Cancer Center performs first-ever prostate cancer treatment
The radiation oncology team at UH Seidman Cancer Center in Cleveland performed the first-ever prostate cancer treatment April 3 using a newly-approved device -- SpaceOAR which enhances the efficacy of radiation treatment by protecting organs surrounding the prostate.

Related Prostate Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...